Residual viraemia in subjects with chronic HIV infection and viral load < 50 copies/ml: The impact of highly active antiretroviral therapy

AIDS

Volumn 19, Issue 16, 2005, Pages 1843-1847

  Palmisano, Lucia ^a,b   Giuliano, Marina ^a   Nicastri, Emanuele ^a   Pirillo, Maria Franca ^a   Andreotti, Mauro ^a   Galluzzo, Clementina M ^a   Bucciardini, Raffaella ^a   Fragola, Vincenzo ^a   Andreoni, Massimo ^a   Vella, Stefano ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

HAART; HIV 1; HIV 1 DNA; Mutations; Plasma HIV 1 RNA

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR;

ADULT; AGED; ANALYSIS OF VARIANCE; ANAMNESIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

EID: 27544501320     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000188426.87538.ed     Document Type: Article

References (12)

1. Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Eng J Med 1999; 340:1605-1613.
2. Dornadula G, Zhang H, VanUitert B, Stern J, Livornese L, Ingerman MJ, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999; 282:1627-1632.
3. Havlir DV, Strain MC, Clerici M, Ignacio C, Trabattoni D, Ferrante P, et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type-1 infected persons treated with suppressive antiretroviral therapy for five years. J Virol 2003; 77:11212-11219.
4. Hermankova M, Ray SC, Ruff C, Powell-Davis M, Ingersoll R, D'Aquila RT, et al. HIV-1 drug resistance profiles in children and adults with viral load of < 50 copies/ml receiving combination therapy. JAMA 2001; 286:196-207.
5. Kieffer TL, Finucane MM, Nettles RE, Quinn TC, Broman KW, Ray SC, et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis 2004; 189:1452-1465.
6. Palmisano L, Giuliano M, Pirillo MF, Galluzzo CM, Andreotti M, Bucciardini R, et al. Baseline predictors and virological outcome in subjects developing mutations during intermittent HAART. Antiviral Ther 2004; 9:S159.
7. Viard JP, Burgard M, Hubert JP, Aaron L, Rabian C, Pertuiset N, et al. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS 2004; 18:45-49.
8. Johnson VA, Brun-Vézinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, et al. Drug-resistance mutations in HIV-1. Top HIV Med 2003; 11:215-221.
9. Klein MB, Willemot P, Murphy T, Lalonde RG. The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection. AIDS 2004; 18:1895-1904.
10. Weiser SD, Guzman D, Riley ED, Clark R, Bangsberg DR. Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence. HIV Clin Trials 2004; 5:278-287.
11. Maggiolo F, Ravasio L, Ripamonti D, Gregis G, Quinzan G, Arici C, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 2005; 1:158-163.
12. Wei X, Liang C, Götte M, Wainberg MA. Negative effect of the M184V mutation in HIV-1 reverse transcriptase on initiation of viral DNA synthesis. Virology 2003; 1:202-212.